Back to Search
Start Over
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: Lack of evidence for induction of chromosomal instability
- Source :
- Leukemia Research. 30:338-342
- Publication Year :
- 2006
- Publisher :
- Elsevier BV, 2006.
-
Abstract
- In several large phase II trials, low-dose treatment with the azanucleoside 5-aza-2'-deoxycytidine (decitabine, DAC) resulted in complete hematologic and cytogenetic responses in 23 and 31% of MDS patients, respectively. The question of induction of chromosomal instability by this demethylating agent was addressed by serial karyotypic analyses. 53/122 DAC-treated patients had all normal metaphases at time of treatment start. In 46/53 patients, sequential cytogenetic analyses were performed. 9/46 patients (20%) acquired clonal chromosomal abnormalities during follow-up (4/9 transient). 8/9 abnormalities were gains or losses of entire chromosomes. The rate and pattern of cytogenetic evolution are thus not higher than in historical MDS cohorts not receiving specific treatment.
- Subjects :
- Male
Antimetabolites, Antineoplastic
Cancer Research
Monosomy
Azacitidine
Decitabine
Biology
chemistry.chemical_compound
Chromosomal Instability
Chromosome instability
medicine
Humans
Metaphase
Aged
Myelodysplastic syndromes
Hematology
Middle Aged
medicine.disease
Demethylating agent
Oncology
chemistry
Myelodysplastic Syndromes
Cytogenetic Analysis
Immunology
DNA methylation
Cancer research
Female
Deoxycytidine
Chromosome Deletion
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 01452126
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Leukemia Research
- Accession number :
- edsair.doi.dedup.....2ce99bbe1d62fe813c1217c454fcd1da